Woodline Partners LP Mei Pharma, Inc. Transaction History

Woodline Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.54 - $2.74 $814,600 - $4.13 Million	-1,508,520 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.33 - $3.37 $50,171 - $72,566	21,533 Added 1.45%	1,508,520 $4.03 Million
Q3 2021 Nov 15, 2021	SELL	$2.52 - $2.99 $2.2 Million - $2.61 Million	-873,629 Reduced 37.01%	1,486,987 $4.1 Million
Q2 2021 Aug 16, 2021	BUY	$2.6 - $3.65 $4.48 Million - $6.29 Million	1,723,275 Added 270.39%	2,360,616 $6.73 Million
Q1 2021 May 17, 2021	BUY	$2.73 - $4.5 $1.74 Million - $2.87 Million	637,341 New	637,341 $2.19 Million

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $366M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.